https://orcid.org/0000-0002-7248-9453
Figures
Abstract
Recently, we reported rifabutin hyper-activity against Acinetobacter baumannii. We sought to characterize if any additional rifamycins (n = 22) would also display hyper-activity when tested in iron-limited media against A. baumannii, K. pneumoniae, and E. coli. MICs were determined against representative clinical isolates using the iron-limited media RPMI-1640. Only rifabutin was hyperactive against A. baumannii.
Citation: Lu P, Alletto F, Lee B, Burk E, Martinez J, Prati F, et al. (2023) Defining the minimum inhibitory concentration of 22 rifamycins in iron limited, physiologic medium against Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae clinical isolates. PLoS ONE 18(6): e0287102. https://doi.org/10.1371/journal.pone.0287102
Editor: Yung-Fu Chang, Cornell University, UNITED STATES
Received: January 18, 2023; Accepted: May 26, 2023; Published: June 13, 2023
Copyright: © 2023 Lu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: This work was supported by National Institute of Allergy and Infectious Diseases (NIAID) grants (R01AI139052 to BL; 2R01AI130060, R01AI117211 to BS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: Authors BL and BS are inventors on a patent for rifabutin therapy for A. baumannii infections and own equity in ExBaq, which has licensed the technology for development. The University of Southern California owns intellectual property related to these development efforts. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Introduction
We previously conducted a modified compound screen assay against Acinetobacter baumannii using RPMI-1640 broth, a medium that better models the in vivo physiologic blood environment as compared to the rich mediumMueller Hinton II broth, cation-adjusted (MHII)). We found that rifabutin (RBT) possesses previously unrecognized hyper-activity against A. baumannii, but only in physiological media, and not in rich media [1–3]. RBT is able to rapidly enter the cell through the FhuE protein, an iron transport protein that is downregulated when the bacteria are replete with iron [1,4]. We have previously tested rifabutin, rifampin, rifaximin, rifapentine, FCE-22250, rifalazil, and rifamycin sv against A. baumannii and only rifabutin was able to traffic through the FhuE protein in iron limited conditions [1]. Here, we sought to determine if any additional, commercially available rifamycins would have increased activity in iron limited conditions when tested against representative isolates of A. baumannii, Klebsiella pneumoniae, and Escherichia coli.
Rifamycin MIC distributions
We determined rifamycin MICs (n = 185) against a larger panel of 21 rifamycin compounds against A. baumannii (n = 5), K. pneumoniae (n = 3), and E. coli (n = 1) clinical isolates using the broth microdilution method per the Clinical & Laboratory Standards Institute (CLSI), but modified to use the iron-limited medium RPMI-1640 as previously described [1–3,5,6]. A summary of the compounds tested is listed in Table 1. Consistent with our previous data, we did observe hyper susceptible RBT phenotypes (MIC < 0.05 mg/L) for the A. baumannii HUMC1 and ATCC17978 isolates [1,2]. However, no isolate for any species tested was hypersusceptible to any other compound tested (Table 1, Fig 1).
CGP-4832
Previous studies have shown that the rifamycin CGP-4832 is able to traffic through the E. coli iron transport protein FhuA [7–9]. CGP-4832 MICs against E. coli MG1655 were 8 mg/L and 0.25 mg/L in MHII and RPMI-1640 respectively. This 32-fold shift in MIC is consistent with the described mechanism of action for CGP-4832 against E. coli. As this mechanism is conceptually similar to the mechanism described for RBT entry, we tested if A. baumannii is hyper susceptible to CGP-4832. However, no benefit was observed for A. baumannii. CGP-4832 MICs against A. baumannii HUMC1 and LAC-4 were 2 mg/L and 4 mg/L respectively in MHII; and 8 mg/L and 2 mg/L respectively in RPMI-1640.
It was previously estimated that about 33% of clinical isolates were hypersusceptible to CGP-4832 [7]. However, this number was determined using only MHII for susceptibility testing because it was not yet known that transport of CGP-4832 through the FhuA protein depended on an iron-limited environment. CGP-4832 MICs were determined against a panel of 45 E. coli clinical isolates, obtained from the CDC and FDA AR Isolate Bank, in MHII or RPMI-1640 to test if a greater proportion of clinical isolates would be hypersusceptible to CGP-4832 if MICs were determined in iron-limited media. There was a significant difference in CGP-4832 and RBT MICs determined in MHII (p = 0.001, Mann-Whitney), but no significant difference when MICs were determined in RPMI-1640. Additionally, there was not a statistically significant difference between the distribution of GCP-4832 MICs determined in the iron-rich MHII as compared to the iron-limited RPMI-1640 media (Fig 2, S1 Table). This result was somewhat surprising because sideromycin antibiotics such as albomycin, also dependent on transport by FhuA, displayed increased activity in iron-limited media [10].
Conclusions
The use of culture media that mimics the in vivo physiologic environment during infection is a valuable tool for characterizing antibiotic activity in vitro. Rifabutin and CGP-4832 are the only rifamycin compounds that are able to traffic through the FhuE protein of A. baumanii or the FhuA protein of E. coli respectively. We have previously shown that rifabutin is not able to enter E. coli through FhuA of E. coli [2]. The library of compounds tested represents broad chemical diversity and will further guide the development of additional derivatives capable of being transported more broadly by both FhuA and FhuE proteins of diverse bacterial species.
Methods
MIC assay
Unless otherwise indicated, the standard broth microdilution method following CLSI methodology was used to determine MICs [5]. The media used for the minimum inhibitory concentration (MIC) assays performed in this study were MHII or RPMI-1640 as previously described [1–3,6,11,12].
Briefly, 100 μL of media was added to the wells in columns 2–10. Column 11 served as a positive growth control and contained only bacteria and media. Column 12 served as the sterility control and contained only culture media without bacteria. Next, 200 μl of a 2X antibiotic working solution was added to the wells in column 1. Two-fold serial dilutions of the antibiotic were performed through column 10. Next, 100 μl of a 1×10⁶ CFU/mL working solution of bacteria were added to each of the wells in columns 1–11. The inoculum concentration was confirmed by plating serial dilutions on TSA plates. MIC plates were incubated at 35±2˚C and results were recorded at 24 hours.
Supporting information
S1 Table. MIC summary.
Distribution of CGP-4832 MICs determined in MHII or RPMI-1640 media against 45 E. coli clinical isolates.
https://doi.org/10.1371/journal.pone.0287102.s001
(CSV)
References
- 1. Luna B, Trebosc V, Lee B, Bakowski M, Ulhaq A, Yan J, et al. A nutrient-limited screen unmasks rifabutin hyperactivity for extensively drug-resistant Acinetobacter baumannii. Nat Microbiol. 2020;5: 1134–1143. pmid:32514072
- 2. Lee B, Yan J, Ulhaq A, Miller S, Seo W, Lu P, et al. In Vitro Activity of Rifabutin and Rifampin against Antibiotic-Resistant Acinetobacter baumannii, Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae. mSphere. 2021;6: e0092021. pmid:34817233
- 3. Cheng J, Yan J, Reyna Z, Slarve M, Lu P, Spellberg B, et al. Synergistic Rifabutin and Colistin Reduce Emergence of Resistance When Treating Acinetobacter baumannii. Antimicrob Agents Chemother. 2021;65. pmid:33468472
- 4. Trebosc V, Schellhorn B, Schill J, Lucchini V, Bühler J, Bourotte M, et al. In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms. J Antimicrob Chemother. 2020. pmid:32869081
- 5.
Performance Standards for Antimicrobial Susceptibility Testing, 32nd edition. Clinical and Laboratory Standards Institute; 2022.
- 6. Miller S, Goy K, She R, Spellberg B, Luna B. Antimicrobial Susceptibility Testing Performed in RPMI 1640 Reveals Azithromycin Efficacy against Carbapenem-Resistant Acinetobacter baumannii and Predicts In Vivo Outcomes in Galleria mellonella. Antimicrob Agents Chemother. 2022; e0132022. pmid:36468875
- 7. Wehrli W, Zimmermann W, Kump W, Tosch W, Vischer W, Zak O. CGP 4832, a new semisynthetic rifamycin derivative highly active against some gram-negative bacteria. J Antibiot. 1987;40: 1733–1739. pmid:2448280
- 8. Pugsley AP, Zimmerman W, Wehrli W. Highly efficient uptake of a rifamycin derivative via the FhuA-TonB-dependent uptake route in Escherichia coli. J Gen Microbiol. 1987;133: 3505–3511. pmid:3332686
- 9. Ferguson AD, Ködding J, Walker G, Bös C, Coulton JW, Diederichs K, et al. Active transport of an antibiotic rifamycin derivative by the outer-membrane protein FhuA. Structure. 2001;9: 707–716. pmid:11587645
- 10. Braun V. Active transport of siderophore-mimicking antibacterials across the outer membrane. Drug Resist Updat. 1999;2: 363–369. pmid:11498352
- 11. Luna BM, Ershova K, Yan J, Ulhaq A, Nielsen TB, Hsieh S, et al. Adjunctive transferrin to reduce the emergence of antibiotic resistance in Gram-negative bacteria. J Antimicrob Chemother. 2019. pmid:31170282
- 12. Ambrose PG, VanScoy BD, Luna BM, Yan J, Ulhaq A, Nielsen TB, et al. Apotransferrin in Combination with Ciprofloxacin Slows Bacterial Replication, Prevents Resistance Amplification, and Increases Antimicrobial Regimen Effect. Antimicrob Agents Chemother. 2019;63. pmid:30782989